Perindopril

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 1, 2006, Pages 63-71

  Alfakih, K ^a   Hall, A S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibition; Coronary heart disease; Heart failure; Hypertension; Perindopril

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN II; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBOXYL GROUP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; INDAPAMIDE; LOOP DIURETIC AGENT; NIFEDIPINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PERINDOPRILAT; POTASSIUM; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEHYDRATION; DIABETES MELLITUS; DIZZINESS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EUROPEAN UNION; FAINTNESS; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; LIPOPHILICITY; NEPHROTOXICITY; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCANDINAVIA; STROKE; STRUCTURE ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PERINDOPRIL;

EID: 30344484813     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.1.63     Document Type: Article

References (33)

1. PFEFFER MA, BRAUNWALD E, MOYE LA et al.: FOR THE SAVE INVESTIGATORS: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. (1992) 327:669-677.
2. THE SOLVD INVESTIGATORS: Effects of enalopril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. (1992) 327:685-691.
3. ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) INVESTIGATORS: Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821-828.
4. KOBER L, TROP-PEDERSON C, CARLSEN JE et al., FOR THE TRANDOLAPRIL CARDIAC EVALUATION (TRACE) STUDY GROUP: A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (1995) 333:1670-1676.
5. WING L, REID C, RYAN P et al., FOR THE SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY GROUP: A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348:583-592.
6. THE HOPE INVESTIGATORS: Effects of angiotensin-converting enzyme inhibitor ramipril, on cardiovascular events in highrisk patients. N. Engl. J. Med. (2000) 342:145-153.
7. THE EUROPA TRIAL INVESTIGATORS: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet (2003) 362:782-788.
8. World Health Organization-International Society Of Hypertension guidelines for the management of hypertension guidelines subcommittee. J. Hypertens. (1999) 17:151-183.
9. TODD PA, FITTON A: Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs (1991) 42:90-114.
10. DINICOLANTONIO R, DOYLE AE: Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1985) 7:937-942.
11. DEVISSAGUET JP, AMMOURY N, DEVISSAGUET M, PERRET L: Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam. Clin. Pharmacol. (1990) 4:175-189.
12. THIOLLET M, FUNCK-BRENTANO C, GRANGE JD et al.: The pharmacokinetics of perindopril in patients with liver cirrhosis. Br. J. Clin. Pharmacol. (1992) 33:326-328.
13. LEES KR: The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J. Hypertens. Suppl. (1992) 10:S3-S11.
14. BUSSIEN JP, D'AMORE TF, PERRET I. et al.: Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin. Pharmacol. Ther. (1986) 39:554-558.
15. VANHOUTTE PM: Endothelium and control of vascular function. State of the art lecture. Hypertension (1989) 13:658-667.
16. HORNIG B, KOHLER C, DREXLER H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115-1118.
17. GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. (1998) 339:1285-1292.
18. ALHENC-GELAS F, SOUBRIER F, HUBERT C et al.: The angiotensin I-converting enzyme (kininase II): progress in molecular and genetic structure. J. Cardiovasc. Pharmacol. (1990) 15(Suppl. 6):S25-S29.
19. LO M, JULIEN C, MICHEL JB et al.: Antirenin immunization versus angiotensin converting enzyme inhibition in rats. Hypertension (1990) 16:80-88.
20. SU JB, BARBE F, CROZATIER B, CAMPBELL DJ, HITTINGER L: Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J. Cardiovasc. Pharmacol. (1999) 34:700-710.
21. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design. Cardiovasc. Drugs. Ther. (2000) 14:671-679.
22. DALY CA, FOX KM, REMME WJ, BERTRAND ME, FERRARI R, SIMOONS ML, EUROPA INVESTIGATORS: The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur. Heart J. (2005) 26:1369-1378.
23. JERUMS G, ALLEN TJ, CAMPBELL DJ et al., ON BEHALF OF THE MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet. Med. (2004) 21(11):1192.
24. MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Comparison between perindopril and nifedipine in hypertensiove and normotensive diabetic patients with microalbuminuria. Br. Med. J. (1991) 302:210-216).
25. PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 29:1033-1041.
26. DUFOUIL C, CHALMERS J, COSKUN O et al., PROGRESS MRI SUBSTUDY INVESTIGATORS: Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 112(11):1644-1650.
27. DAHLOF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366:895-906.
28. SPEIRS C, WAGNIART F, POGGI L: Perindopril postmarketing surveillance: a 12 month study in 47 351 hypertensive patients. Br. J. Clin. Pharmacol. (1998) 46:63-70.
29. STRAUSS MH, LONN EM, VERMA S: Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur. Heart J. (2005) 26(22):2351-2353.
30. STOSCHITZKY K: The EUROPA Trial. Lancet (2003) 362:1935-1936.
31. BRAUNWALD E, DOMANSKI MJ, FOWLER SE et al.:. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. (2004) 351:2058-2068.
32. EUROPA-PERTINENT INVESTIGATORS: PERTINENT-Perindopril-Thrombosis, Inflammation, Endothelial Dysfunction and Neurohormonal Activation Trial: a substudy of the EUROPA study. Cardiovasc. Drugs Ther. (2003) 17:83-91.
33. BOTS ML, REMME WJ, LUSCHER TF GROBBEE DE: PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study-sub study of EUROPA: rationale and design. Cardiovasc. Drugs Ther. (2002) 16:227-236.